A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment

Cancer type: Lung cancer

Phase: II

Principal Investigator: Brunsvig Paal

Country: NO

Keywords: Norway, AUY922, NSCLC, Novartis, Oslo

Status: Completed

Link to